Abstract:Abstract Abstract 3768 Objective: To investigate the effect of bone marrow-derived mensenchymal stem cells modified by mouse interferon-γ gene on experimental liver fibrosis in mice. Methods: (1) Mesenchymal stem cells (MSCs) derived from BM in BALB/c mice were cultured and identified by the flow cytometry. (2) The Ad-mIFN-γ, a recombinant adenoviral vector encoding mouse IFN-γ gene obtained by PCR from the vector pORF5-mIFN-γ, was created with the AdEasy Adenoviral Vector System. (3) MSCs were transfected with Ad-mIFN-γ. The transfection efficiency was detected by the flow cytometry at 24 hours after infection to determine the best multiplicity of infection (MOI). (4) The liver fibrosis of BALB/c mice were induced with concanavalin A (Con A) challenge weekly for six times. Then MSCs modified by the recombinant adenovirus encoding mouse IFN-γ gene were infused to BALB/c mice induced with Con A at the 24 hours after the first dose. The behavioral changes of mice were monitored closely. One week after the last dose of Con A, all mice were sacrificed and the fibrosis indexes were assessed by several histopathology methods systemicly. Moreover, hepatic hydroxyproline and serum parameters for liver fibrosis and liver function were evaluated and serum mIFN-γ concentrations were measured, respectively. Results: (1) The flow cytometry confirmed that the cells we obtained were MSCs. (2) The target gene mIFN-γ amplified by PCR from the vector pORF5-mIFN-γ, was identified by sequencing, which proved that the mIFN-γ gene was consisted of 468 nucleotides and was completely the same as the sequence published on GenBank. The target gene mIFN-γ was cut out by double endonucleases and then connected to the shuttle vector pAdTrack-CMV. Then the newly constructed vector was linearized by Pme I following transformed to the E.coli. BJ5183, which has the backbone vector of pAdEasy-1. The correct recombinant pAd-mIFN-γ was selected by endonucleases and by Kanamycin resistance and was transfected into AD-293 cells to obtain the adenoviral vector Ad-mIFN-γ. The Ad-mIFN-γ can be propagated in AD-293 cell line, the titre of which was 3.2×109 pfu/ml. (3) MSCs modified by recombinant adenovirus encoding mIFN-γ (IFN-γ/GFP-MSCs) at different multiplicity of infection (MOI) were detected by the flow cytometry. The optimal MOI for Ad-mIFN-γ was 400 with the transfection efficiency of 80.4%, and the optimal MOI for Ad-control was 200 with the transfection efficiency of 72.3%. (4) The changes of liver tissue and serum parameters for liver fibrosis showed liver fibrosis were reducd more obviously in the group treated with IFN-γ/GFP-MSCs (p<0.05), and liver functions were also improved more obviously in this group (p<0.05). The histopathology study using HE staining, masson trichrome staining and silver staining demonstrated that the structure of liver became much better in mice treated with IFN-γ/GFP-MSCs, with liver fibrosis improved significantly. Conclusion: Bone marrow-derived mensenchymal stem cells modified by mouse interferon-γ can reduce liver fibrosis and improve liver function on immuo-mediated liver fibrosis in mice induced by Con A. Disclosures: No relevant conflicts of interest to declare.

Gene delivery with IFN-γ-expression plasmids enhances the therapeutic effects of MSCs on DSS-induced mouse colitis

IL-37b Gene Transfer Enhances the Therapeutic Efficacy of Mesenchumal Stromal Cells in DSS- Induced Colitis Mice

IFN-γ Promoted Exosomes from Mesenchymal Stem Cells to Attenuate Colitis Via Mir-125A and Mir-125B

[Ifn-Γ Stimulation Enhances Immunosuppressive Capability of Human Umbilical Cord Mesenchymal Stem Cells].

Enhanced Immunosuppression of T Cells by Sustained Presentation of Bioactive Interferon-γ Within Three-Dimensional Mesenchymal Stem Cell Constructs

Pre-treatment with IL-1β Enhances the Efficacy of MSC Transplantation in DSS-induced Colitis

Dual-Functionalized MSCs That Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects on Inflammatory Bowel Disease.

IDDF2018-ABS-0243 TSG-6 released by mesenchymal stem cells derived from human induced pluripotent stem cells alleviate colitis through the regulation of CD44

Interferon- priming enhances the therapeutic effects of menstrual blood-derived stromal cells in a mouse liver ischemia-reperfusion model

<p>IFN-?-Primed hUCMSCs Significantly Reduced Inflammation via the Foxp3/ROR-?t/STAT3 Signaling Pathway in an Animal Model of Multiple Sclerosis</p>

IGF-1C hydrogel improves the therapeutic effects of MSCs on colitis in mice through PGE2-mediated M2 macrophage polarization

Systemic Infusion of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Experimental Colitis in Mice

Transplantation of IFN-γ Primed Hucmscs Significantly Improved Outcomes of Experimental Autoimmune Encephalomyelitis in a Mouse Model

Bone Marrow-Derived Mensenchymal Stem Cells Modified by Mouse Interferon-γ Gene Reduce Fibrosis and Improve Function in a Mouse Model of Liver Fibrosis.

Effective enhancement of the immunomodulatory capacity of canine adipose-derived mesenchymal stromal cells on colitis by priming with colon tissue from mice with colitis

Thermally Engineered Msc-Derived Exosomes Ameliorate Colitis in Mice by Restoring the Imbalanced Th17/Treg Cell Ratio

Bone Marrow-Derived CXCR4-overexpressing MSCs Display Increased Homing to Intestine and Ameliorate Colitis-Associated Tumorigenesis in Mice.

The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease.

Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells Alleviate Dextran Sulfate Sodium-Induced Colitis by Increasing Regulatory T Cells in Mice

Interleukin-25 Primed Mesenchymal Stem Cells Achieve Better Therapeutic Effects on Dextran Sulfate Sodium-Induced Colitis Via Inhibiting Th17 Immune Response and Inducing T Regulatory Cell Phenotype

Thermally engineered MSC-derived extracellular vesicles ameliorate colitis in mice by restoring the imbalanced Th17/Treg cell ratio